Dosing Guidance Lacking For Leading COVID-19 Antiviral Therapies, ASHP Analysis Shows
Health-system pharmacist organization assesses the evidence behind off-label use of existing drugs for COVID-19, along with top investigational prospects like Gilead’s remdesivir.
